Tumor Necrosis Factor-Alpha Inhibitor Associated Psoriasiform Alopecia

April 2012 in “ Informa Healthcare eBooks ”

Tumor Necrosis Factor-alpha Inhibitor psoriasiform alopecia TNF-alpha inhibitors psoriasiform scalp plaques hair loss topical steroids intralesional triamcinolone catagen phase telogen phase sebaceous glands peribulbar inflammation plasma cells steroids triamcinolone

Studysummary Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on informahealthcare.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

research Scarring Alopecia Associated With the Epidermal Growth Factor Receptor Inhibitor Erlotinib

32 citations , April 2011 in “Journal of the American Academy of Dermatology”

Erlotinib may cause scarring hair loss.

Psoriatic Alopecia/Alopecia Areata–Like Reactions Secondary to Anti–Tumor Necrosis Factor-α Therapy: A Novel Cause of Noncicatricial Alopecia

research Psoriatic Alopecia/Alopecia Areata–Like Reactions Secondary to Anti–Tumor Necrosis Factor-α Therapy: A Novel Cause of Noncicatricial Alopecia

72 citations , February 2011 in “The American Journal of Dermatopathology”

This study found that anti-TNF therapy-induced alopecia exhibits distinct clinical and histopathological features and can mimic psoriatic alopecia and alopecia areata, with some patients improving with topical treatment.

research Tufted Hair Folliculitis in a Woman Treated with Trastuzumab

28 citations , October 2010 in “Targeted Oncology”

This case report presents an instance of tufted hair folliculitis in a woman treated with trastuzumab, highlighting a previously unreported skin side effect of this selective HER2 inhibitor.

research Alopecia Areata as Another Immune-Mediated Disease Developed in Patients Treated with Tumor Necrosis Factor-Alpha Blocker Agents

61 citations , June 2010 in “Journal of the European Academy of Dermatology and Venereology”

This study highlights cases of alopecia areata that developed during anti-TNF-α therapy, suggesting a potential link or increased frequency, particularly among individuals with a personal or family history of autoimmune diseases.

research A Case Report of Inflammatory Nonscarring Alopecia Associated with the Epidermal Growth Factor Receptor Inhibitor Erlotinib

33 citations , June 2009 in “Journal of Cutaneous Pathology”

This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.

research Alopecia Areata Following Adalimumab

38 citations , January 2009 in “Journal of Cutaneous Medicine and Surgery”

This case report highlights a woman who developed new-onset alopecia areata after starting adalimumab for psoriatic arthritis, challenging the assumed role of TNF-alpha in the condition's pathogenesis.